{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_modifications_structuralModifications_molecularFragment_refPname in (root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Status:
Investigational
Source:
NCT04093596: Phase 1 Interventional Active, not recruiting Relapsed/Refractory Multiple Myeloma
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:dabocemagene autoficel [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:orvacabtagene autoleucel [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NADA141542
(2021)
Source URL:
First approved in 2021
Source:
NADA141542
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:bulevirtide [INN]
Source URL:
Class:
PROTEIN
